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Abstract
Background: Signalling by fibroblast growth factor receptor type 2 (FGFR2) normally involves a tissue-specific
alternative splice choice between two exons (IIIb and IIIc), which generates two receptor isoforms (FGFR2b and
FGFR2c respectively) with differing repertoires of FGF-binding specificity. Here we describe a unique chimeric IIIb/c
exon in a patient with Apert syndrome, generated by a non-allelic homologous recombination event.
Case Presentation: We present a child with Apert syndrome in whom routine genetic testing had excluded the
FGFR2 missense mutations commonly associated with this disorder. The patient was found to harbour a
heterozygous 1372 bp deletion between FGFR2 exons IIIb and IIIc, apparently originating from recombination
between 13 bp of identical DNA sequence present in both exons. The rearrangement was not present in the
unaffected parents.
Conclusions: Based on the known pathogenesis of Apert syndrome, the chimeric FGFR2 protein is predicted to
act in a dominant gain-of-function manner. This is likely to result from its expression in mesenchymal tissues,
where retention of most of the residues essential for FGFR2b binding activity would result in autocrine activation.
This report adds to the repertoire of rare cases of Apert syndrome for which a pathogenesis based on atypical
FGFR2 rearrangements can be demonstrated.
Background
Apert syndrome (AS) is a severe malformation disorder
with a birth prevalence of ~1 in 65,000, characterised by
craniosynostosis (premature fusion of the cranial sutures)
and bony or cutaneous syndactyly of the hands and feet
[1]. Over 98% of cases are caused by one of two heterozy-
gous mutations in exon IIIa of the fibroblast growth fac-
t o rr e c e p t o r2g e n e( FGFR2), encoding the amino acid
substitutions Ser252Trp or Pro253Arg (Figure 1A; [2]).
Many other pathogenic missense mutations of FGFR2
have been described in patients with craniosynostosis
(typically with diagnoses of Crouzon, Pfeiffer or Beare-
Stevenson syndromes) but these are associated with less
severe abnormalities of the limbs than are present in
Apert syndrome [3]. FGFR2 is one of four transmem-
brane FGFRs that mediate signalling downstream of
fibroblast growth factor ligands (FGFs) and plays an
important role in skeletal development and disease [4].
The mechanism underlying the exquisite genotype-
phenotype correlation of Apert syndrome mutations
(Figure 1A) needs to be understood in terms of the
biology of FGF/receptor signalling and the structural
pathophysiology of FGFR2 mutations [5,6]. The FGFR2
protein comprises three extracellular immunoglobulin-
like domains (IgI, IgII, IgIII), a transmembrane (TM)
domain and a cytoplasmic tyrosine kinase (TK)
domain. Signalling occurs by trans-phosphorylation of
the TK domains following dimerisation of receptor
molecules mediated by binding extracellular FGF in a
2:2 complex [7]. Specificity of FGF binding is deter-
mined by the IgII and IgIII domains, and further ela-
borated by the mutually exclusive alternative splicing
of exons IIIb and IIIc (Figure 1A) resulting in isoforms
FGFR2b and FGFR2c respectively, which differ in the
sequence of the second half of the IgIII domain.
FGFR2b is expressed in ectoderm and interacts with
specific FGFs (FGF3, FGF7, FGF10, FGF22) in the
underlying mesenchyme while FGFR2c is restricted to
mesenchyme and interacts with a wider repertoire of
FGFs expressed in the ectoderm [8]. The narrow
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determined by four key residues encoded near the
beginning of the IIIb exon that provide specific con-
tacts for FGF10 and related ligands [9]. The two com-
mon AS mutations (Ser252Trp and Pro253Arg)
introduce additional contacts with multiple FGFs. This
results both in enhanced FGFR2c signalling mediated
by physiological FGFs, and in illegitimate binding by
mesenchymally expressed FGFs creating an autocrine
loop [10-13]; reviewed by [5,14].
Figure 1 Genome and sequence context of deletion in FGFR2. A. Schematic representation of FGFR2 around deleted region (red arrows);
alternative splicing normally yields FGFR2b and FGFR2c spliceforms (yellow and turquoise lines respectively). Positions of previously described AS
mutations are shown in blue; asterisks indicate recurrent missense mutations, downward arrows indicate Alu insertions, horizontal arrows
represent the deletion. Other missense mutations of exons IIIa, IIIb and TM are not associated with AS (black asterisks). Intronic splicing
enhancer/silencer (ISE/ISS) and exonic splicing silencer (ESS) elements are indicated with arrows (UISS - upstream intronic splicing silencer, DISS -
downstream intronic splicing silencer, ISAR - intronic splicing activator and repressor). B. PCR of 2.5 kb region including exon IIIc, revealing a
deletion in the patient (P) of ~1.4 kb compared to the control (C; N - negative control). Absence of normal-sized fragment in the patient sample
is attributable to preferential amplification of the deleted allele. C. Sequence chromatogram of PCR products from 1B. The patient’s chimeric
exon is aligned with control exon IIIb and IIIc sequences. The 13 bp region of identity is shown between the red lines (fwd, forward and rvs,
reverse sequence). D. Amino acid alignment of exons IIIb, IIIc, and the chimeric exon created by the deletion. Specific contacts for FGF10 and
FGF2 are highlighted in yellow and turquoise respectively. Region of identity between exons is underlined.
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have been three Alu insertions and one deletion
reported as causing AS [15,16]. Although in all cases the
rearrangements affect exon IIIc rather than exon IIIa,
this can nevertheless be understood in terms of a shared
pathophysiological mechanism with the common AS
mutations. It was shown experimentally that one of
these rearrangements drove illegitimate expression of
the FGFR2b splice form in fibroblasts, a mesenchymal
derivative [16]. Hence the common factor linking exon
IIIa missense mutations and exon IIIc rearrangements,
both causing AS, appears to be the autocrine activation
of signalling by FGF10 and/or related ligands in the
mesenchyme [6,14-18].
Here, we report a patient with AS caused by a variant
of this latter rearrangement mechanism, in whom a 1.4
kb deletion caused by non-allelic homologous recombi-
nation between exons IIIb and IIIc has given rise to a
chimeric IIIb/IIIc exon in which the reading frame is
maintained.
Case Presentation
The affected boy was the first child of healthy, non-con-
sanguineous parents aged 24 years (mother) and 35
years (father) at the time of birth. He was born at term
weighing 3.26 kg and noted to have a dysmorphic facial
appearance with turribrachycephaly, open metopic
suture, shallow orbits, a deviated nasal septum and high
arched, non-cleft palate. Bilateral dacrocystocoeles were
present. In addition he had broad radially deviated
thumbs, skin syndactyly of digits 2-4 in the hands and
feet, and broad medially deviated great toes (Figure 2).
Three-dimensional computed tomography of the skull
demonstrated bicoronal synostosis; magnetic resonance
imaging of the brain showed normal intracranial struc-
tures. Cervical spine radiographs were normal, but C1
and C2 were not well visualised. Developmental pro-
gress was normal at the age of 4 years and 11 months.
A clinical diagnosis of Apert syndrome was proposed
and blood obtained for genetic testing. However, two dif-
ferent diagnostic labs were unable to identify any patho-
genic variants after DNA sequence analysis of the IIIa
and IIIc exons of FGFR2. Further DNA sequence analysis
of additional exons of FGFR2, and other genes in which
mutations have been identified in craniosynostosis syn-
dromes (FGFR1, FGFR3 and TWIST1) was also negative.
We designed a long-range PCR assay to further inves-
tigate the region around exon IIIc of FGFR2, looking for
evidence of Alu insertions or other rearrangements.
Amplification of a 2.5 kb region including exons IIIb
and IIIc (forward primer 984 bp upstream of exon IIIb,
5’-GAATTTCAGAAGGGAACTATGGAGTAG-3’,
reverse primer 32 bp downstream of exon IIIc, 5’-
ATAGCAGTCAACCAAGAAAAGGG-3’) revealed an
apparent deletion in the patient sample of ~1.4 kb com-
pared to the control (Figure 1B). DNA sequencing of
this product confirmed the presence of a 1372 bp dele-
tion with the breakpoints occurring in a 13 bp region of
perfect homology shared by the IIIb and IIIc exons (Fig-
ure 1C). This deletion results in a chimeric IIIb/IIIc
exon that retains the open-reading frame and comprises
the first 63 bp of exon IIIb, the 13 bp region of homol-
ogy, and the final 63 bp of exon IIIc. The deletion was
not present in either parental sample indicating that it
had arisen de novo in the child. Permission was not
given to determine the parental origin of the deletion.
Discussion
The deletion identified in this patient is likely to have
arisen by non-allelic homologous recombination between
Figure 2 Clinical features of Apert syndrome in the patient. A,
B. Note high flat skull (turribrachycephaly) associated with
radiologically proven bicoronal synostosis. C-F. Note broad radially
deviated thumbs, skin syndactyly of digits 2-4 in the hands and feet,
and broad medially deviated great toes (C, post-operative after
syndactyly release).
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IIIc exons, and is expected to have two consequences.
First, loss of competition between the alternative exons
IIIb and IIIc may result in either constitutive splicing, or
skipping, of the chimeric exon (however skipping would
result in an out-of-frame translation product). Second, the
chimeric exon will retain some particular IIIb or IIIc-like
structural features, but lose others.
The selection of a particular exon (IIIb or IIIc) for
FGFR2 splicing is mediated by cis elements either in the
adjacent intron (intronic splicing enhancer/silencer: ISE/
ISS) or within the exon itself (exonic splicing silencer:
ESS) that bind splicing regulatory proteins to either pro-
mote or inhibit tissue-specific splicing. To date, several
of these elements have been identified in the intron
separating FGFR2 e x o n sI I I ba n dI I I c ,a sw e l la so n e
upstream of exon IIIb, one downstream of exon IIIc,
and three within the exons (Figure 1A; [19]). Recently it
has been shown that in the absence of tissue-specific
regulators, FGFR2c is the default spliceform due to the
stronger 3’ splice site of exon IIIc and the presence of
ISS and ESS elements around exon IIIb [20]. In epithe-
lial cells, epithelial splicing regulatory proteins (ESRPs)
bind to the ISE/ISS-3 element, suppressing use of the
downstream exon IIIc 3’ splice site and activating spli-
cing of exon IIIb [20,21]. The deletion described here
removes the entire intron between exons IIIb and IIIc,
and therefore all known regulatory elements within this
intron, as well as an ESS from each exon. It is difficult
to predict exactly how the chimeric exon would be pro-
cessed in vivo, but the AS phenotype of the child, which
implies a gain-of-function mechanism, does indicate
that production of FGFR2 containing the in-frame chi-
meric exon is likely to occur in critical target tissues; by
contrast, skipping of both exons IIIb and IIIc would
generate an isoform with loss-of-function properties
[22].
The crystal structures of the FGFR2 isoforms and
their ligands reveal specific contacts between receptor
loops present either in FGFR2b or in FGFR2c, and the
distinct FGFs with which they interact [9,23]. The dele-
tion in the patient causes several of these contacts to be
lost. However, four of five key residues for FGF10 bind-
ing are retained, making it likely that FGFR2b properties
persist in the chimeric exon (Figure 1D).
Conclusions
The case described here further demonstrates the speci-
fic mutational pathophysiology of AS, which results
either from one of two missense substitutions in exon
IIIa, or disruptions of exon IIIc splicing. The chimeric
exon created by the deletion in this patient falls into the
latter category. The encoded protein is predicted to
retain FGFR2b-like binding properties, and hence lead
to autocrine activation of mesenchymal signalling
mediated by FGF10 or a related ligand.
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